Scilex Holding Company · NASDAQ:SCLX
Scilex — SPAC Merger (December 2021)
57 slides from Scilex's SPAC merger presentation, December 2021
Slide 1: Innovative Leader in Non-Opioid Pain Therapeutics
Scilex Holding Company Innovative Leader in Non-Opioid Pain Therapeutics December 2021 Confonfiidentdentiialal:: F C Foror IIn ntte errnalnal S SCCIILE LEX XPPh hararm macaceuteutiiccalalss U Use se On Onllyy 1
Slide 2: Safe Harbor Statements
Scilex Holding Company Safe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this “Presentation”), along with certain statements that may be made by management of Scilex Holding Company (together with its subsidiaries, “Scilex”) orally in pres
Slide 3: Industry and Market Data, Important Information
Scilex Holding Company undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Scilex’s expectations. Industry and Market Data Certain data in this Presen
Slide 4: Where to Find It; Participants in the Solicitation
Scilex Holding Company Investors and security holders of the SPAC are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that the SPAC files with the SEC when, and if, they become available because they
Slide 5: Non-Solicitation
Scilex Holding Company Scilex and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of the SPAC in connection with the Proposed Business Combination. Information about Scilex’s directors and executive officers and informat
Slide 6: Agenda
Scilex Holding Company Agenda 1) Scilex Holding Corporate Overview 2) ZTlido® 1.8% Update 3) SP-102 (SEMDEXA) for Lumbar Radicular Pain / Sciatica 4) SP-103 (3X ZTlido) for Low Back Pain 5) DBR Low Dose Naltrexone (LDN) for Fibromyalgia 6) Company Summary
Slide 7: Corporate Overview
Scilex Holding Company Corporate Overview Confidential: For Internal SCILEX Pharmaceuticals Use Only 10
Slide 8: Business Combination with Vickers Vantage Corp I
Scilex Holding Company Scilex Business Combination with Vickers Vantage Corp I Vickers Vantage Corp. I Vickers Strengths IPO Overview: Strong deal structuring, investing and M&A experience within the fin-tech space Gross Proceeds: $138.0 Million Significant private and public investment IPO Date: Ja
Slide 9: Executive Management Team
Scilex Holding Company Scilex Executive Management Team Name Position(s) Experience 25+ years of management experience in large Pharma and Biotech CEO & President Lead commercialization of multiple blockbusters Rituxan®, Abilify®, Pegasys®, BuSpar®, Tequin Jaisim Shah CEO, Semnur Pharma; CBO,
Slide 10: Best-in-Class Non-Opioid Pain Therapeutics
Scilex Holding Company Best-in-Class Non-Opioid Pain Therapeutics Phase3 Platform Program IND Phase 1 Phase 2 Pivotal NDA Approved Upcoming Milestones ZTlido® 1.8% (Postherpetic Launched US October 2018 Neuralgia-PHN) SP-102 (SEMDEXA) (Lumbar Radicular / Non-Opioid Pivotal Phase 3 trial enrollment S
Slide 11: 2021 Scilex Business Update
Scilex Holding Company 2021 Scilex Business Update In April 2021, Scilex received a supplemental new drug application (sNDA) approval from the FDA for ZTlido to expand the label for use in water stress conditions In 2020, ZTlido had US net sales ~$27MM, which represents a ~35% growth rate YoY 2019 ●
Slide 12: Target Physicians
Scilex Holding Company 15,000-20,000 Target Physicians Consist of a Mix of Health Care Specialists, Focus in High Volume Clinics Physicians treating neuropathic and chronic back pain Neurology Significant concentration Orthopedic in high volume clinics surgeons 10% Anesthesiologists 4% • ~3,000 pain
Slide 13: Company Headquarters
Scilex Holding Company Scilex Holding Company Headquarters - 960 San Antonio Road, Palo Alto CA 94303 - Satellite Office: 4955 Directors Place, San Diego, CA 92121
Slide 14: ZTlido 1.8% for Post-Herpetic Neuralgia (PHN)
Scilex Holding Company Scilex Pharmaceuticals ZTlido 1.8% for Post-Herpetic Neuralgia (PHN) Confidential: For Internal SCILEX Pharmaceuticals Use Only 10
Slide 15: Marketed Product: ZTlido 1.8%
Scilex Holding Company Marketed Product: ZTlido® 1.8% (FDA approved for relief of pain associated with PHN) ® Lidocaine Patch MarketOverview >3.5 million prescriptions per year More than 129 million prescription lidocaine patches were US FDA APPROVAL – FEBRUARY 2018 sold in the US in 2020 according
Slide 16: Lidocaine Patches are as Efficacious as Gabapentinoids
Scilex Holding Company Lidocaine Patches are as Efficacious as Gabapentinoids
Slide 17: ZTlido Prescription Growth vs Lidocaine Market
Scilex Holding Company ZTlido strong prescription growth continued at faster pace than market through 2020, despite COVID-19 pandemic impact Lidocaine Market Annual TRx & NRx ZTlido Annual TRx & NRx NRx TRx NRx TRx 4,000,000 250,000 3,660,193 3,500,000 3,342,642 +9.5 YoY ∆ 199,144 200,000 3,000,000
Slide 18: ZTlido YTD Sales Performance Comparison
Scilex Holding Company ZTlido YTD Sales Performance Comparison ZTlido Gross Sales YTD '21 vs '20 (Jan-Oct) $60.0 +35% ∆ $50.0 $40.0 $30.0 $51.8MM $20.0 $38.5MM $10.0 $0.0 YTD 2020 (Jan-Oct) YTD 2021 (Jan-Oct)
Slide 19: ZTlido Market Access continuing to improve
Scilex Holding Company ZTlido Reimbursement Market Access Update: Preferred Lido patch on Medi-Cal from Jan 1. Negotiating with CVS ZTlido Market Access continuing to improve ZTlido MHC Notable Contracts: Signed & In-Negotiations ESI/Cigna Part-D CVS/Aetna Part D Elixir Elixir 3.7 7.6 FEP BCBS Comme
Slide 20: ZTlido Global Intellectual Property
Scilex Holding Company ZTlido Global Intellectual Property Family 1 – Expiring in 2031 ● U.S. 9,283,174 – Non-aqueous patch comprising lidocaine – Orange Book listed ● U.S. 9,925,264 – Methods of treating pain using patch – Orange Book listed ● U.S. 9,931,403 – Non-aqueous patch comprising lidocaine
Slide 21: ZTlido Summary
ZTlido Summary ZTlido sales continues to show impressive growth 2 years after launch (growth of 35% in 2020, projected strong growth in 2021) Effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs (United Health and Op
Slide 22: SP-102 (SEMDEXA) for Lumbar Radicular Sciatica Pain
Scilex Holding Company SP-102 (SEMDEXA) for Lumbar Radicular Sciatica Pain Confidential: For Internal SCILEX Pharmaceuticals Use Only 10
Slide 23: Epidural Steroid Injections One of the Most Common Procedures
Scilex Holding Company Epidural Steroid Injections One of the Most Common Medical Procedures and Top Pain Procedure in the U.S. Common Surgical Strong Growth Rate, Evidenced by Procedures (thousands) (1) Medicare Procedure Volumes Epidural Steroid Injections 10,000 All cardiac interventions 7,500 Op
Slide 24: Focus on Non-narcotic Pain Management Driving ESI Growth
Scilex Holding Company Focus on Non-narcotic Pain Management Driving ESI Growth Prescription opioid abuse is at epidemic proportions in the U.S.1 Current Additionally, research shows that opioids do not provide clinically Problem meaningful pain relief in patients with low back and radicular pain2 M
Slide 25: Important Environmental Factors
Scilex Holding Company Important Environmental Factors Fungal Meningitis Outbreak with ESI (2013-14)
Slide 26: CDC Data: Drug Overdose Deaths Top 100K
Scilex Holding Company CDC Data: Drug Overdose Deaths Top 100K for First Time 26
Slide 27: SP-102: On-Track to be First Novel Epidural Steroid with FDA Label
SP-102: On-Track to be the First Novel Epidural Steroid Formulation with an FDA-approved Label to Treat Sciatica ✔Potent non-particulate steroid (injectable dexamethasone sodium phosphate viscous gel) ✔Pre-filled syringe for epidural use ✔Gel formulation for extended local release and substantial ma
Slide 28: SEMDEXA – Product Development & Regulatory
Scilex Holding Company SEMDEXA – Product Development & Regulatory Confidential: For Internal SCILEX Pharmaceuticals Use Only 27
Slide 29: Preclinical Supporting Studies
Scilex Holding Company Preclinical Supporting Studies Hydrodynamic Animal Study SP-102 Toxicology Program Addition of viscosity agent results in a dose All tox studies completed concurrence with FDA pre- dependent prolongation of the residency time of IND meeting the product within the epidural spac
Slide 30: Phase 1/2 Trial in Patients with Radicular Pain
Scilex Holding Company Phase 1/2 Trial in Patients with Radicular Pain: SP-102 Led to a Continuous Reduction in Leg Pain and Back Pain Phase 1/2 Open-Label Crossover Study in Patients with Radicular Pain (PK/PD Bridging) Mean change from baseline in pain scores (N=12) SP-102 single IV dexamethasone
Slide 31: SP-102 Phase 2 – Repeat Dose Trial
Scilex Holding Company SP-102 Phase 2 – Repeat Dose Trial NPRS: Numeric Pain Rating Scale • Clinical Response (over 50% pain reduction) with Average Leg Pain • Greater effect with second treatment, demonstrating added benefit • Cortisol Suppression Time is not extended by repeat dose • No interferen
Slide 32: SP-102 Pivotal Phase 3 C.L.E.A.R. Trial Topline Results
Scilex Holding Company SP-102 Pivotal Phase 3 C.L.E.A.R. Trial Topline Results
Slide 33: SP-102 C.L.E.A.R. Phase 3 Trial Objectives
Scilex Holding Company SP-102 C.L.E.A.R. Phase 3 Trial Objectives Primary objective: ● Evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single transforaminal (TF) injection of SP-102 compared to an intramuscular injectio
Slide 34: Phase 3 SP-102 C.L.E.A.R. Trial Design
Scilex Holding Company Phase 3 SP-102 C.L.E.A.R. Trial Design (Corticosteroid Lumbar Epidural Analgesia for Radiculopathy) Inclusion Radicular leg pain episode (4-9 NPRS) MRI confirmed No prior ESI (epidural steroid injection) No opioids or NSAIDs Stable, >4 avg NPRS pain in 21d screening Primary En
Slide 35: Phase 3 C.L.E.A.R. Trial – Sample Size
Scilex Holding Company Phase 3 SP-102 C.L.E.A.R. Trial – Sample Size Statistical Analysis Plan ● The sample size provides 90% power to detect a 1-point difference in change from Baseline in the mean NPRS average daily leg pain score in the affected leg over 4 weeks between the 2 treatment groups. ●
Slide 36: Phase 3 C.L.E.A.R. Trial – Primary Endpoint
Scilex Holding Company Phase 3 SP-102 C.L.E.A.R. Trial – Primary Endpoint Change in Average Daily Pain in Affected Leg 0.5 0 Week 1 Week 2 Week 3 Week 4 Numeric Pain Rating Scale, LS Mean -0.5 -1 Placebo n=189 -1.5 Comparison: SP-102 vs. Placebo Over 4 Weeks, LS Mean (SE) -1.08 (0.17) 95% CI -1.42,
Slide 37: Oswestry Disability Index
Scilex Holding Company Oswestry Disability Index The gold standard for measuring degree of disability and estimating quality of life in a person with low back pain. Contains 10 topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function
Slide 38: C.L.E.A.R. Trial – Key Secondary Endpoints
Scilex Holding Company C.L.E.A.R. Trial – Key Secondary Endpoints Disability Improvement Days to Open-Label Repeat Injection 0 SP-102 Placebo SP-102 Placebo -2 n=154 n=189 (N=154) (N=189) LS Mean Change from Baseline -4 Number of subjects with repeat 70 (46%) 126 (67%) Oswestry Disability Index inje
Slide 39: C.L.E.A.R. Trial – Adverse Events
Scilex Holding Company C.L.E.A.R. Trial – Adverse Events SP-102/SP-102 PBO/SP-102 SP-102/none PBO/none (N=104) (N=130) (N=98) (N=69) Subjects, n(%) Events Subjects, n(%) Events Subjects, n(%) Events Subjects, n(%) Events Any TEAE 34 (32.7) 72 41 (31.5) 73 25 (25.5) 46 14 (20.3) 23 Any TEAE >3% Incid
Slide 40: Phase 3 C.L.E.A.R. Trial - Conclusions
Scilex Holding Company Phase 3 SP-102 C.L.E.A.R. Trial - Conclusions The trial met primary and key secondary endpoints with statistical significance Demonstrated clear safety profile of SP-102 Achieved all study objectives Next steps in 2022 ● Apply for Breakthrough Therapy Designation with FDA ● Re
Slide 41: SP-102 Manufacturing On-Track for NDA Submission in 2023
Scilex Holding Company The SP-102 Manufacturing On-Track for NDA Submission to FDA in 2023 Commercial supply chain in place API: Dexamethasone sodium phosphate supplier in place Novel excipient: Supply from leading commercial provider, 20-year supply agreement for specific type for use Drug pr
Slide 42: SP-102 (SEMDEXA) Global Intellectual Property
Scilex Holding Company SP-102 (SEMDEXA) Global Intellectual Property Patent family expiring in 2036 ● U.S. 10,117,938 - methods of treating inflammation and/or pain ● U.S. 10,500,284 – composition of matter and syringe ● U.S. 11,020,485 – composition of matter ● 1 pending U.S. application Ex-U.S. ap
Slide 43: Summary SP-102 (SEMDEXA)
Scilex Holding Company Summary SP-102 (SEMDEXA) No FDA approved products to treat Sciatica/chronic back pain. All currently used off-label products have FDA warnings not to use Scilex will meet with FDA to discuss NDA filing for SEMDEXA in 2022 Breakthrough Designation filing with Phase 3 results in
Slide 44: SEMDEXA – Commercial Strategy & Outlook
Scilex Holding Company SEMDEXA – Commercial Strategy & Outlook Confidential: For Internal SCILEX Pharmaceuticals Use Only 34
Slide 45: SEMDEXA Overall Physician Impression
Scilex Holding Company SEMDEXA Overall Physician Impression Source: “Lumbar Radiculopathy Market Opportunity” Quantitative Research (Nov’17); Cognitive Consulting
Slide 46: SEMDEXA – Broad Potential for Life Cycle Management
Scilex Holding Company SEMDEXA – Broad Potential for Life Cycle Management Physicians indicated there is potential opportunity for spontaneous use of SEMDEXA outside of lumbar radiculopathy which could represent an additional upside of ~50-200%* over LR Additional Uses Carpel Tunnel Hip and Knee
Slide 47: SP-102 Reimbursement Scenario
Scilex Holding Company SP-102 Reimbursement Scenario SP-102 is expected to be used in the Office setting as well as in Ambulatory Surgical Centers and Hospital Outpatient clinics Scilex expects SP-102 to secure favorable pricing and reimbursement due to its strong product profile, meeting important
Slide 48: High Barriers to Competition
Scilex Holding Company High Barriers to Competition Intellectual Property • SP-102 Method of Use: US Patent issued (2036 expiry) • SP-102 Formulation: US Patent approved (2036 expiry); ex-US major markets issued and pending Proprietary Excipient • Exclusive supply agreement for novel biologic excipi
Slide 49: Summary – SP-102 (SEMDEXA)
Scilex Holding Company Summary – SP-102 (SEMDEXA) Market with high unmet need & no FDA approved products to treat sciatica pain Scilex will meet with FDA to discuss NDA for SEMDEXA in 2022 and pursue Breakthrough Designation and Priority Review applications SEMDEXA is a potential blockbuster product
Slide 50: SP-103 for Low Back Pain & Delayed Release LDN for Fibromyalgia
Scilex Holding Company SP-103 for Low Back Pain & Delayed Release LDN for Fibromyalgia Confidential: For Internal SCILEX Pharmaceuticals Use Only 31
Slide 51: SP-103 is a Next-Generation, Triple Strength Formulation of ZTlido 1.8%
Scilex Holding Company SP-103 is a Next-Generation, Triple Strength Formulation of ZTlido 1.8% SP-103 Next-Generation, 5.4% Lidocaine Topical System Superior adhesion and drug formulation efficiency with 3x drug load (108 mg vs 36 mg lidocaine) only 36mg of lidocaine Triple strength localized
Slide 52: SP-104 Delayed Burst Low Dose Naltrexone – Fibromyalgia
Scilex Holding Company SP-104 Delayed Burst Low Dose Naltrexone (LDN) – Fibromyalgia Fibromyalgia is a long-term condition that causes pain all over the body and affects ~2% of general population (5-8 million patients, 80-90% women) Low Dose Naltrexone (LDN) efficacy well documented • Routinely used
Slide 53: Summary
Scilex Holding Company Summary Confidential: For Internal SCILEX Pharmaceuticals Use Only 46
Slide 54: Acute/Chronic Pain Major Global Healthcare Problem
Scilex Holding Company Acute/Chronic Pain Major Global Healthcare Problem • Pain is reported in about 90% of the global population • 94% report pain in their back or lower back • 69% of people endure long-lasting pain which negatively impacts quality of life Source: Global Pain Index Summary Report.
Slide 55: Best-in-Class Non-Opioid Pain Therapeutics
Scilex Holding Company Best-in-Class Non-Opioid Pain Therapeutics Phase3 Platform Program IND Phase 1 Phase 2 Pivotal NDA Approved Upcoming Milestones ZTlido® 1.8% (Postherpetic Launched US October 2018 Neuralgia-PHN) SP-102 (SEMDEXA) (Lumbar Radicular / Non-Opioid Pivotal Phase 3 trial enrollment S
Slide 56: ESI Market a Huge Opportunity for a Potential Blockbuster Like SP-102
Scilex Holding Company Epidural Steroid Injections (ESIs) Market are a Huge Opportunity for a Potential Blockbuster Like SP-102 Pursuing a proven strategy for novel locally-delivered products for pain indications Osteoarthritis intra- Post-operative acute pain Chronic low back pain articular injecti
Slide 57: Summary
Scilex Holding Summary Commercial non-opioid pain management company with 3 clinical stage programs in large markets with very high unmet need Launched rapidly growing ZTlido (lidocaine topical system 1.8%) in 2018 with in-house commercial and sales team Semnur Pharma merged with Scilex in 2019 and